Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
HKSE:08189's PB Ratio is ranked worse than 98.39% of 248
companies
in the Agriculture industry
Industry Median: 1.565
vs HKSE:08189: 25.50
During the past 12 months, Tianjin TEDA Biomedical Engineering Co's average Book Value Per Share Growth Rate was -50.00% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -47.30% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was -41.70% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was -30.80% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Tianjin TEDA Biomedical Engineering Co was 19.10% per year. The lowest was -47.30% per year. And the median was -4.00% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Tianjin TEDA Biomedical Engineering Co PB Ratio Related Terms
Tianjin TEDA Biomedical Engineering Co PB Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Tianjin TEDA Biomedical Engineering Co PB Ratio Chart
Tianjin TEDA Biomedical Engineering Co Annual Data
For the Agricultural Inputs subindustry, Tianjin TEDA Biomedical Engineering Co's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Tianjin TEDA Biomedical Engineering Co PB Ratio vs Agriculture Industry
Tianjin TEDA Biomedical Engineering Co PB Ratio Calculation
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Tianjin TEDA Biomedical Engineering Co (HKSE:08189) has a PB Ratio of 42.50 as of Aug. 28, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Tianjin TEDA Biomedical Engineering Co and its competitors. This is 1701% above median its historical median of 2.36. Over the past decade, Tianjin TEDA Biomedical Engineering Co's PB Ratio has ranged from 0.54 to 59.17. According to the industry distribution chart, Tianjin TEDA Biomedical Engineering Co ranks #244 out of 248 companies in the Agriculture industry, placing it in the top 98.4%.
Is Tianjin TEDA Biomedical Engineering Co's PB Ratio too high?
Tianjin TEDA Biomedical Engineering Co's current PB Ratio of 42.50 is 1701% above median its 10-year median of 2.36. Over the past 10 years, this metric has ranged from a low of 0.54 to a high of 59.17. The Agriculture industry median PB Ratio is 1.57. Tianjin TEDA Biomedical Engineering Co's value of 42.50 is 2615.7% above this industry median. Based on the distribution chart, Tianjin TEDA Biomedical Engineering Co ranks #244 out of 248 companies in the Agriculture industry, which is in the bottom quartile relative to peers. Overall, Tianjin TEDA Biomedical Engineering Co has a GF Score™ of 28/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Tianjin TEDA Biomedical Engineering Co's PB Ratio compare to CTVA and CF?
According to the Agriculture industry distribution chart, Tianjin TEDA Biomedical Engineering Co ranks #244 out of 248 companies for PB Ratio. This places Tianjin TEDA Biomedical Engineering Co in the lower half of its industry. The industry median PB Ratio is 1.57. Tianjin TEDA Biomedical Engineering Co's value of 42.50 is 2615.7% above this benchmark. Historically, Tianjin TEDA Biomedical Engineering Co's own PB Ratio has ranged from 0.54 to 59.17 over the past decade. While the company's 10-year median is 2.36 vs. the industry median of 1.57, Tianjin TEDA Biomedical Engineering Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for an Agriculture company?
The median PB Ratio among Agriculture companies is 1.57, based on 248 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Tianjin TEDA Biomedical Engineering Co's current PB Ratio of 42.50 is 2615.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Tianjin TEDA Biomedical Engineering Co and its competitors. For the Agriculture industry, the median PB Ratio is 1.57 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Tianjin TEDA Biomedical Engineering Co's current PB Ratio is 42.50, which is 1701% above median its own 10-year median of 2.36. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tianjin TEDA Biomedical Engineering Co stock overvalued right now?
Based on GuruFocus' analysis, Tianjin TEDA Biomedical Engineering Co (HKSE:08189) is currently considered Significantly Overvalued. The stock's GF Value™ is HK$0.19, compared to a current price of HK$0.26 — trading 34.2% above its estimated fair value. The current PB Ratio is 42.50, which is 1701% above median its 10-year median of 2.36 and 2615.7% above the Agriculture industry median of 1.57. Tianjin TEDA Biomedical Engineering Co's overall GF Score™ is 28/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Tianjin TEDA Biomedical Engineering Co (HKSE:08189), the current PB Ratio is 42.50 as of Aug. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Tianjin TEDA Biomedical Engineering Co (HKSE:08189) Overvalued in 2026?
Based on GuruFocus' analysis, Tianjin TEDA Biomedical Engineering Co stock appears to be overvalued.
The current stock price of HK$0.26 is trading 34.2% above its estimated GF Value™ of HK$0.19.
GuruFocus considers Tianjin TEDA Biomedical Engineering Co to be Significantly Overvalued.
Key valuation signals for HKSE:08189:
PB Ratio: 42.50 (1701% above median its 10-year median of 2.36)
GF Value™: HK$0.19 vs. price of HK$0.26 (34.2% above fair value)
Industry Position: 2615.7% above the Agriculture median (#244 of 248)
No single metric tells the full story. See the HKSE:08189 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Tianjin TEDA Biomedical Engineering Co Ltd principally engages in manufacture and sale of biological compound fertiliser products and elderly care and health care services and related products. The group is principally engaged in manufacturing and selling biological compound fertilisers, AI health & elderly care products and services. It operates in two segments namely; fertilisers products; and AI health & elderly care products and services. The company generates a majority of its revenue from the Fertilisers products segment. The People's Republic of China is the primary geographical market for the company.
28GF Score
Get the complete analysis for HKSE:08189
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:08189 has been successfully added to your 
